Acetylcholinesterase inhibitory activities of some flavonoids from the root bark of
 Pinus krempfii
 Lecomte:
 in vitro
 and
 in silico
 study

Cuong, Nguyen Manh; Khanh, Pham Ngoc; Nhung, Le Thi Hong; Ha, Nguyen Xuan; Hương, Trần Thu; Bauerová, Katarína; Kim, Young Ho; Tung, Do Dinh; Thủy, Trịnh Thị; Anh, Nguyễn Thị Hoàng

doi:10.1080/07391102.2023.2223664

Cited by 3 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This neurodegenerative disease often begins with minor memory loss and may progress to cognitive deficits, serious behavior issues, or mortality [ 1 ]. The development and precise origins of Alzheimer’s disease are still largely unclear; however, the most often advanced arguments include amyloid, metal, and cholinergic activity [ 2 ]. The current medication for AD focuses on increasing acetylcholine (ACh) levels by inhibiting cholinesterase enzyme (ChE) activities [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

“…The development and precise origins of Alzheimer’s disease are still largely unclear; however, the most often advanced arguments include amyloid, metal, and cholinergic activity [ 2 ]. The current medication for AD focuses on increasing acetylcholine (ACh) levels by inhibiting cholinesterase enzyme (ChE) activities [ 2 ]. Indeed, the current primary treatment strategies for AD are based on targeting the acetylcholine (ACh) level, a critical neurotransmitter for signal transduction.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anti-Cholinergic Effects of the Phenolic Extract from the Astragalus crenatus Plant: A Computational and Network Pharmacology Study

Lekmine,

Benslama,

Tahraoui

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Investigations into cholinesterase inhibition have received attention from researchers in recent years for the treatment of Alzheimer’s disease. Cholinesterase enzymes, namely, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), hold pivotal significance in Alzheimer’s disease (AD) treatment. In this study, we utilized the ethanolic extract of Astragalus crenatus followed by liquid chromatography–electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) to separate and identify at least 21 compounds in the extract. Rosmarinic acid exhibited the highest concentration (96.675 ± 1.3 mg/g extract), succeeded by hesperidin (79.613 ± 1.2 mg/g extract), hesperetin (75.102 ± 1.4 mg/g extract), rutin (68.156 ± 1.6 mg/g extract), chlorogenic acid (67.645 ± 1.5 mg/g extract), fisetin (66.647 ± 2.3 mg/g extract), and hyperoside (63.173 ± 1.5 mg/g extract). A. crenatus extract efficiently inhibited both AChE and BChE activities in a dosage-dependent manner. Molecular docking was employed to scrutinize the anticholinesterase mechanisms of the identified phytocompounds. Notably, a network pharmacology analysis was executed for the most efficacious compound. Based on binding energies, hesperidin emerged as the most potent inhibitor against both AChE and BChE, exhibiting scores of −10.5 Kcal/mol and −9.8 Kcal/mol, respectively. Due to its dual inhibition of AChE and BChE activities, hesperidin from Astragalus crenatus holds promise for the development of novel therapeutics aimed at neurological disorders, particularly AD.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%